Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 119
Filter
1.
Biochim Biophys Acta ; 1833(5): 1006-16, 2013 May.
Article in English | MEDLINE | ID: mdl-23328083

ABSTRACT

Sphingosine kinase 1 (SPHK1) overexpression in malignant cells has been reported. Mouse Friend cells showed higher SPHK1 but not SPHK2 expression compared with other mouse cell lines. A Sphk1 promoter analysis demonstrated the region between -53bp and the first exon as the minimal promoter. Further promoter truncation revealed the importance of a MYB-binding site. EMSA using this region as the probe demonstrated one band containing c-MYB protein, and its intensity decreased during erythroid differentiation with hexamethylane bisacetamide (HMBA), a potent inducer of erythroid differentiation of Friend cells. ChIP assay also revealed in vivo binding of c-MYB. c-MYB overexpression and siRNA for c-Myb affected SPHK1 expression, confirming the important regulatory role of c-MYB in SPHK1 expression. HMBA reduced c-MYB expression rapidly. Induced differentiation by HMBA caused a marked and rapid reduction of SPHK1 mRNA, protein and enzyme activity leading to the rapid decrease of cellular sphingosine 1-phosphate level. Moreover, terminally differentiated cells did not resume SPHK1 expression. Compared with original Friend cells, stable overexpression of wild-type SPHK1 showed higher cell proliferation, resistance to cell death by serum depletion. Interestingly, HMBA-induced differentiation of these cells was delayed but not completely suppressed. In contrast, SPHK inhibitor and its siRNA inhibited cell growth and enhanced HMBA-induced differentiation significantly, suggesting that SPHK1 delayed HMBA-induced differentiation by its cell proliferation-promoting activity. Effects of pertussis toxin, a G-protein-coupled receptor inhibitor, and S1P receptor antagonist on Friend cell growth and differentiation were negligible, suggesting the importance of the intracellular SPHK1/S1P signaling in Friend cells.


Subject(s)
Cell Differentiation/genetics , Phosphotransferases (Alcohol Group Acceptor) , Proto-Oncogene Proteins c-myb , Receptors, Lysosphingolipid , Animals , Cell Line , Down-Regulation , Humans , Mice , Phosphotransferases (Alcohol Group Acceptor)/genetics , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Promoter Regions, Genetic , Proto-Oncogene Proteins c-myb/genetics , Proto-Oncogene Proteins c-myb/metabolism , RNA, Messenger/genetics , RNA, Small Interfering , Receptors, Lysosphingolipid/antagonists & inhibitors , Receptors, Lysosphingolipid/genetics , Receptors, Lysosphingolipid/metabolism , Signal Transduction
2.
J Thromb Haemost ; 10(10): 2099-107, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22906111

ABSTRACT

BACKGROUND: Intron 22 inversion (Inv22) of the coagulation factor (F)VIII gene (F8) is a frequent cause of severe hemophilia A. In addition to Inv22, a variety of F8 mutations (1492 unique mutations) causing hemophilia A have been reported, of which 171 involve deletions of over 50 bp (HAMSTeRs database; http://hadb.org.uk/). However, only 10% of these large deletions have been fully characterized at the nucleotide level. PATIENTS AND METHODS: We investigated gene abnormalities in three unrelated severe hemophilia A patients with high titer FVIII inhibitors. They had previously been shown to carry large deletions of the F8, but the precise gene abnormalities remain to be elucidated. RESULTS: Inverse shifting-PCR (IS-PCR) Inv22 diagnostic tests revealed that these patients carried either type I or II Inv22. However, they showed a wild-type (WT) pattern in the IS-PCR Inv22 complementary tests. We further analyzed their X chromosomes to account for the puzzling results, and found that they had different centromeric breakpoints in the Inv22 X chromosomes, adjacent to the palindromic regions containing int22h-2 or -3, and their spacer region, respectively. The connections appeared to be shifted towards the telomere of the WT F8 Xq28, resulting in a new telomere with an additional intact int22h copy. CONCLUSIONS: These gene rearrangements might result from double-strand breaks in the most distal regions of the long arms of the Inv22 X chromosomes, followed by DNA restorations using the WT F8 Xq28 by non-homologous end joining or break-induced replication; thus leading to large F8 deletions in severe hemophilia A patients.


Subject(s)
Autoantibodies/blood , Base Sequence , Factor VIII/genetics , Factor VIII/immunology , Hemophilia A/genetics , Hemophilia A/immunology , Sequence Deletion , Sequence Inversion , Adolescent , Adult , Chromosome Breakpoints , Chromosome Mapping , Chromosomes, Human, X , DNA Breaks, Double-Stranded , DNA Mutational Analysis , DNA Repair , Gene Rearrangement , Genetic Predisposition to Disease , Hemophilia A/blood , Humans , Introns , Inverted Repeat Sequences , Male , Phenotype , Polymerase Chain Reaction , Severity of Illness Index , Telomere/genetics
3.
Biochem Biophys Res Commun ; 383(4): 411-6, 2009 Jun 12.
Article in English | MEDLINE | ID: mdl-19364496

ABSTRACT

Janus kinase 2 (JAK2) V617F mutation has been regarded as the major cause of myeloproliferative disorders (MPD). However, the mechanisms of abnormal cell growth by JAK2V617F have not been elucidated. In this study, cell cycle regulatory protein expression was analyzed using JAK2V617F-Ba/F3 and mock-Ba/F3. JAK2V617F-Ba/F3, but not mock-Ba/F3, showed IL-3 independent cell growth and constitutive STATs activation. Deregulation of p27(Kip1), the cell cycle regulator at the G1 to S transition, was observed in JAK2V617F-Ba/F3 but not in mock-control. p27(Kip1) deregulation was not due to p27(Kip1) mRNA level but due to high Skp2 expression, a subunit of ubiquitin E3 ligase, through the STAT binding in the Skp2 promoter. Like JAK2V617F overexpression, constitutively active STAT5 or STAT3 induced aberrant p27(Kip1) expression of Ba/F3 cells. Similar findings were observed in BCR/ABL-transfected Ba/F3. Our results elucidate the regulatory mechanism by which JAK2V617F modulates Skp2 gene expression through the STAT transcription factors.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p27/metabolism , Gene Expression Regulation , Janus Kinase 2/metabolism , S-Phase Kinase-Associated Proteins/genetics , STAT Transcription Factors/metabolism , Animals , Cell Line, Tumor , Electrophoretic Mobility Shift Assay , Interleukin-3/metabolism , Janus Kinase 2/genetics , Mice , Mutation , Promoter Regions, Genetic
4.
Leukemia ; 23(7): 1270-7, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19212333

ABSTRACT

Although oncogenic functions and the clinical significance of Wilms tumor 1 (WT1) have been extensively studied in acute leukemia, the regulatory mechanism of its transcription still remains to be determined. We found a significant correlation among the amounts of WT1, GATA-1 and GATA-2 mRNAs from leukemia and solid tumor cell lines. Overexpression and small interfering RNA (siRNA) transfection experiments of GATA-1 and GATA-2 showed that these GATA transcription factors could induce WT1 expression. Promoter analysis showed that the 5' promoter did not explain the different WT1 mRNA levels between cell lines. The 3' enhancer, especially the distal sites out of six putative GATA binding sites located within the region, but not the intron 3 enhancer, were essential for the WT1 mRNA level. Electrophoretic mobility shift assay (EMSA) showed both GATA-1 and GATA-2 bound to these GATA sites. Besides acute leukemia cell lines, solid tumor cell lines including, TYK-nu-cPr also showed a high level of WT1 mRNA. We showed that GATA-2 expression is a determinant of WT1 mRNA expression in both TYK-nu-cPr cells and HL60 cells without GATA-1 expression. Taken together, these results suggest that GATA-1 and/or GATA-2 binding to a GATA site of the 3' enhancer of WT1 played an important role in WT1 gene expression.


Subject(s)
Enhancer Elements, Genetic , GATA1 Transcription Factor/metabolism , GATA2 Transcription Factor/metabolism , Genes, Wilms Tumor , Leukemia/genetics , Transcription, Genetic , Acute Disease , Base Sequence , Cell Line, Tumor , Chromatin Immunoprecipitation , DNA Primers , Electrophoretic Mobility Shift Assay , GATA1 Transcription Factor/genetics , GATA2 Transcription Factor/genetics , Humans , Introns , Leukemia/pathology , Promoter Regions, Genetic , RNA, Messenger/genetics , RNA, Small Interfering , Reverse Transcriptase Polymerase Chain Reaction
5.
Haemophilia ; 14(5): 1088-93, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18540891

ABSTRACT

Female carriers of haemophilia B are usually asymptomatic; however, the disease resulting from different pathophysiological mechanisms has rarely been documented in females. In this study, we investigated the mechanisms responsible for haemophilia B in fraternal female twins. We sequenced the factor IX gene (F9) of the propositus, her father, a severe haemophilia B patient and the other family members. X chromosome inactivation was assessed by the methylation-sensitive HpaII-PCR assay using X-linked polymorphisms in human phosphoglycerate kinase 1 gene (PGK1) and glutamate receptor ionotropic AMPA 3 gene (GRIA3). The twins were found to be heterozygotes with a nonsense mutation (p.Arg384X) inherited from their father. The propositus, more severely affected twin, exhibited a significantly higher percentage of inactivation in the maternally derived X chromosome carrying a normal F9. The other twin also showed a skewed maternal X inactivation, resulting in a patient with mild haemophilia B. Thus, the degree of skewing of maternal X inactivation is closely correlated with the coagulation parameters and the clinical phenotypes of the twins. Furthermore, we identified a crossing-over in the Xq25-26 region of the maternal X chromosome of the more severely affected twin. This crossing-over was absent in the other twin, consistent with their fraternal state. Differently skewed X inactivation in the fraternal female twins might cause moderately severe and mild haemophilia B phenotypes, respectively.


Subject(s)
Diseases in Twins/genetics , Hemophilia B/genetics , Twins, Dizygotic/genetics , X Chromosome Inactivation , Blotting, Southern/methods , Factor IX/genetics , Female , Haplotypes , Humans , Infant , Mutation, Missense , Pedigree , Polymerase Chain Reaction/methods
6.
Oncogene ; 27(46): 6023-33, 2008 Oct 09.
Article in English | MEDLINE | ID: mdl-18574469

ABSTRACT

Sphingosine kinase 1 (SPHK1) is overexpressed in solid tumors and leukemia. However, the mechanism of SPHK1 overexpression by oncogenes has not been defined. We found that v-Src-transformed NIH3T3 cells showed a high SPHK1 mRNA, SPHK1 protein and SPHK enzyme activity. siRNA of SPHK1 inhibited the growth of v-Src-NIH3T3, suggesting the involvement of SPHK1 in v-Src-induced oncogenesis. v-Src-NIH3T3 showed activations of protein kinase C-alpha, signal transducers and activators of transcription 3 and c-Jun NH(2)-terminal kinase. Their inhibition suppressed SPHK1 expression in v-Src-NIH3T3, whereas their overexpression increased SPHK1 mRNA in NIH3T3. Unexpectedly, the nuclear run-on assay and the promoter analysis using 5'-promoter region of mouse SPHK1 did not show any significant difference between mock- and v-Src-NIH3T3. Furthermore, the half-life of SPHK1 mRNA in mock-NIH3T3 was nearly 15 min, whereas that of v-Src-NIH3T3 was much longer. Examination of two AU-rich region-binding proteins, AUF1 and HuR, that regulate mRNA decay reciprocally, showed decreased total AUF1 protein associated with increased tyrosine-phosphorylated form and increased serine-phosphorylated HuR protein in v-Src-NIH3T3. Modulation of AUF1 and HuR by their overexpression or siRNA revealed that SPHK1 mRNA in v-Src- and mock-NIH3T3 was regulated reciprocally by these factors. Our results showed, for the first time, a novel mechanism of v-Src-induced SPHK1 overexpression.


Subject(s)
Oncogene Protein pp60(v-src)/physiology , Phosphotransferases (Alcohol Group Acceptor)/genetics , RNA Stability/physiology , RNA-Binding Proteins/physiology , Animals , Antigens, Surface/genetics , Antigens, Surface/metabolism , Antigens, Surface/physiology , Cell Line, Transformed , Cell Proliferation/drug effects , ELAV Proteins , ELAV-Like Protein 1 , Gene Expression Regulation, Enzymologic , Half-Life , Heterogeneous Nuclear Ribonucleoprotein D0 , Heterogeneous-Nuclear Ribonucleoprotein D/genetics , Heterogeneous-Nuclear Ribonucleoprotein D/metabolism , Heterogeneous-Nuclear Ribonucleoprotein D/physiology , Mice , Models, Biological , NIH 3T3 Cells , Oncogene Protein pp60(v-src)/antagonists & inhibitors , Oncogene Protein pp60(v-src)/genetics , Phosphotransferases (Alcohol Group Acceptor)/metabolism , RNA Stability/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Regulatory Sequences, Ribonucleic Acid/physiology , Signal Transduction/genetics , Signal Transduction/physiology , Transfection
7.
Haemophilia ; 14(3): 556-63, 2008 May.
Article in English | MEDLINE | ID: mdl-18397285

ABSTRACT

Type 2A von Willebrand disease (VWD) is characterized by decreased platelet-dependent function of von Willebrand factor (VWF); this in turn is associated with an absence of high-molecular-weight multimers. Sequence analysis of the VWF gene from two unrelated type 2A VWD patients showed an identical, novel, heterozygous T-->G transversion at nucleotide 4508, resulting in the substitution of L1503R in the VWF A2 domain. This substitution, which was not found in 60 unrelated normal individuals, was introduced into a full-length VWF cDNA and subsequently expressed in 293T cells. Only trace amount of the mutant VWF protein was secreted but most of the same was retained in 293T cells. Co-transfection experiment of both wild-type and mutant plasmids indicated the dominant-negative mechanism of disease development; as more of mutant DNA was transfected, VWF secretion was impaired in the media, whereas more of VWF was stored in the cell lysates. Molecular dynamic simulations of structural changes induced by L1503R indicated that the mean value of all-atom root-mean-squared-deviation was shifted from those with wild type or another mutation L1503Q that has been reported to be a group II mutation, which is susceptible to ADAMTS13 proteolysis. Protein instability of L1503R may be responsible for its intracellular retention and perhaps the larger VWF multimers, containing more mutant VWF subunits, are likely to be mal-processed and retained within the cell.


Subject(s)
Molecular Biology , Mutation/genetics , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , Adolescent , Amino Acid Substitution/genetics , DNA Mutational Analysis , Deamino Arginine Vasopressin/therapeutic use , Epistaxis/drug therapy , Exons/genetics , Female , Gene Expression , Hemostasis/drug effects , Hemostasis/genetics , Humans , Male , Middle Aged , Models, Molecular , Platelet Adhesiveness/physiology , Polymerase Chain Reaction , Recombinant Proteins , Structure-Activity Relationship , Transfection , von Willebrand Diseases/physiopathology , von Willebrand Factor/biosynthesis
8.
Int J Hematol ; 87(3): 266-75, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18283525

ABSTRACT

We recently reported increased sphingosine kinase 1 (SPHK1) and decreased neutral sphingomyelinase 2 (NSMase2) gene expression in myelodysplastic syndromes and acute leukemia. This alteration is supposed to change the cellular sphingolipid metabolites; however, positive correlations were observed between daunorubicin (DA)-IC50 and the SPHK1 message but not between DA-IC50 and NSMase2 messages, when 16 different leukemia cell lines were used to analyze the relationship between gene expressions and chemosensitivity against DA. Using two cell lines with either the highest or lowest SPHK1 expression, cellular ceramides and sphingosine 1-phosphate (S1P) were quantified by liquid chromatography/mass spectrometry. Increased ceramide was observed in DA-sensitive, but not in DA-resistant cell lines treated with low doses of DA. Upon DA treatment, S1P decreased more in the sensitive cell lines than in resistant cell lines. A SPHK inhibitor recovered the DA sensitivity of DA-resistant cells. The modulation of SPHK1 gene expression by either overexpression or using siRNA affected the DA sensitivity of representative cell lines. Results clearly show that SPHK1 is both a good marker to predict the DA sensitivity of leukemia cells and a potential therapeutic target for leukemia with high SPHK1 expression, and suggest that the sphingolipid rheostat plays a significant role in DA-induced cytotoxicity.


Subject(s)
Antibiotics, Antineoplastic/pharmacology , Daunorubicin/pharmacology , Drug Resistance, Neoplasm/physiology , Leukemia/drug therapy , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Biomarkers/blood , Cell Line, Tumor , Gene Expression Profiling , Humans , Lysophospholipids/metabolism , Phosphotransferases (Alcohol Group Acceptor)/drug effects , Sphingosine/analogs & derivatives , Sphingosine/metabolism
9.
Oncogene ; 26(12): 1802-10, 2007 Mar 15.
Article in English | MEDLINE | ID: mdl-16964281

ABSTRACT

It was reported that short interfering RNA (siRNA) of EWS/Fli-1 downregulated phospholipase D (PLD)2 in Ewing's sarcoma (EWS) cell line, suggesting that PLD2 is the target of aberrant transcription factor, EWS/Fli-1. Here, we further investigated the regulation of PLD2 gene expression by EWS/Fli-1 and Fli-1 in another EWS cell line, and also in EWS/Fli-1- or Fli-1-transfected cell line. EWS/Fli-1- or Fli-1-overexpressed cells showed higher PLD2 but not PLD1 protein expression and enhanced cell proliferation as compared to mock transfectant. The treatment of these cells with 1-butanol or siRNA of PLD2 inhibited cell growth, suggesting the pivotal role of PLD in cell growth promotion. PLD2 but not PLD1 mRNA level was also increased in EWS/Fli-1 or Fli-1-transfectants. After determining the transcription initiation points, we cloned the 5' promoter of both PLD1 and PLD2 and analysed promoter activities. Results showed that EWS/Fli-1 and Fli-1 increase PLD2 gene expression by binding to an erythroblast transformation-specific domain (-126 to -120 bp from the transcription initiation site) of PLD2 promoter, which is the minimal and most powerful region. Electrophoresis mobility shift assay using truncated proteins showed that both DNA-binding domain and trans-activating domain were necessary for the enhanced gene expression of PLD2.


Subject(s)
Microfilament Proteins/physiology , Oncogene Proteins, Fusion/physiology , Phospholipase D/genetics , Promoter Regions, Genetic , Proto-Oncogene Protein c-fli-1/physiology , Receptors, Cytoplasmic and Nuclear/physiology , Base Sequence , Cell Line , DNA Primers , Electrophoretic Mobility Shift Assay , Humans , Immunoprecipitation , Microfilament Proteins/metabolism , Oncogene Proteins, Fusion/metabolism , Protein Binding , Proto-Oncogene Protein c-fli-1/metabolism , RNA-Binding Protein EWS , Receptors, Cytoplasmic and Nuclear/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Trans-Activators , Transfection
11.
J Thromb Haemost ; 4(9): 2003-9, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16961607

ABSTRACT

OBJECTIVE: To elucidate the molecular consequences of hereditary protein S (PS) deficiency, we investigated the in vitro synthesis of the PS missense mutants in COS-1 cells and their activated protein C (APC) cofactor activities. PATIENTS: Four patients with quantitative PS deficiency suffering from venous thrombosis were examined. RESULTS: We identified three distinct novel missense mutations, R275C, P375Q and D455Y, and two previously reported missense mutations, C80Y and R314H. The P375Q and D455Y mutations were found in one patient and observed to be in linkage on the same allele. The R314H mutant showed the lowest level of expression (32.7%), and the C80Y, P375Q + D455Y, and R275C mutants exhibited a moderate impairment of expression, that is, 43.8%, 49.5%, and 72.3% of the wild type, respectively. Furthermore, pulse-chase experiments demonstrated that all mutants showed impaired secretion and longer half-lives in the cells than the wild type PS. In the APC cofactor assays, the C80Y mutant showed no cofactor activity, and the R275C mutant showed reduced activity, 62.3% of the wild type PS, whereas the R314H and P375Q + D455Y mutants exhibited normal cofactor activity. CONCLUSION: These data indicate that the C80Y and R275C mutations affect the secretion and function of the PS molecule, and that the R314H and P375Q + D455Y mutations are responsible for only secretion defects, causing the phenotype of quantitative PS deficiency observed in the patients.


Subject(s)
Mutation, Missense , Protein S Deficiency/genetics , Protein S/genetics , Adult , DNA Mutational Analysis , Female , Gene Expression Regulation , Genetic Linkage , Half-Life , Humans , Male , Middle Aged , Protein S/metabolism
12.
Haemophilia ; 12(2): 172-8, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16476093

ABSTRACT

We investigated the molecular basis of a severe factor V (FV) deficiency in a Japanese female, and identified two distinct mutations in the FV gene, a novel cytosine insertion (1943insC) and a previously reported point mutation (A5279G). We expected the patient to be a compound heterozygote for those mutations, as a 1943insC, but not an A5279G, was found in the mother and a sibling. The 1943insC will cause a frame-shift after 590Gln, resulting in amino acid substitutions with two abnormal residues followed by a stop codon in the FV A2 domain (FS592X). The A5279G will cause an amino acid alteration in the FV A3 domain (Y1702C), which has been observed in several ethnic groups. We found that both mutant mRNAs were detected by reverse transcriptase polymerase chain reaction (RT-PCR) in the patient's platelets, whereas no FV antigen and activity were detected in plasma. On the one hand, the RT-PCR signal from the FS592X-FV mutant mRNA was markedly reduced, suggesting that the RNA surveillance system would eliminate most of the abnormal FS592X-FV transcripts with a premature termination. On the other hand, expression analyses revealed that only small amounts of Y1702C-FV with a low specific activity were secreted, and that the FS592X-FV was not detected in cultured media. These data indicated that both mutant FV molecules would be impaired, at least in part, during the post-transcriptional process of protein synthesis and/or in secretion. Taken together, it seems to suggest that each gene mutation could be separately responsible for severe FV deficiency, while this phenotype is due to the in-trans combination of the two defects.


Subject(s)
Factor V Deficiency/genetics , Factor V/genetics , Mutation , Adult , Amino Acid Sequence , Animals , Base Sequence , COS Cells , Chlorocebus aethiops , DNA Mutational Analysis/methods , Female , Heterozygote , Humans , Molecular Sequence Data , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods
13.
J Neurochem ; 95(4): 940-9, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16135093

ABSTRACT

Sphingosine kinase (SPHK) is known to exert an anti-apoptic role in various cells and cell lines. We previously reported that human brain is rich in SPHK1 (Murate et al. 2001). After showing a high expression of SPHK1 in rat brain, we examined the gene expression mechanism using nerve growth factor (NGF)-stimulated rat PC12 cells. With RT-PCR, we found that both rat brain and PC12 utilized exon 1d mostly out of eight untranslated first exons. NGF induced an increase in SPHK enzyme activity and protein about double those in PC12 cells, and NGF-induced SPHK1 mRNA was three times higher than in the control. The minimal 5' promoter was determined, and TrkA specific inhibitor K252a inhibited the NGF-induced promoter activity of SPHK1. The truncation or mutation of putative transcription factor-binding motifs revealed that one specificity protein 1 (Sp1) binding motif of the 5' region of exon 1d is prerequisite. Electrophoresis mobility shift assay confirmed the promoter analysis, indicating increased Sp1 protein binding to this motif after NGF treatment. Chromatin immunoprecipitation assay also showed the binding of Sp1 and the promoter region in vivo. These results suggest the signal transduction pathway from NGF receptor TrkA to transcription factor Sp1 protein binding to the promoter Sp1-like motif in NGF-induced rat SPHK1 gene expression.


Subject(s)
Gene Expression Regulation/physiology , Gene Expression/drug effects , Nerve Growth Factor/pharmacology , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Sp1 Transcription Factor/physiology , Animals , Blotting, Western/methods , Brain/metabolism , Carbazoles/pharmacology , Chromatin Immunoprecipitation/methods , Electrophoretic Mobility Shift Assay/methods , Enzyme Inhibitors/pharmacology , Exons , Gene Expression/physiology , Gene Expression Regulation/drug effects , Indole Alkaloids , Luciferases/metabolism , Mutagenesis/physiology , PC12 Cells , Pheochromocytoma/pathology , Phosphotransferases (Alcohol Group Acceptor)/genetics , Promoter Regions, Genetic/physiology , Protein Binding/drug effects , Protein Binding/physiology , RNA, Messenger/metabolism , Rats , Reverse Transcriptase Polymerase Chain Reaction/methods , Transfection/methods
15.
Ann Oncol ; 13(6): 928-43, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12123339

ABSTRACT

BACKGROUND: The aim of the study was to determine factors affecting the toxicity and efficacy of rituximab monotherapy in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma (MCL). PATIENTS AND METHODS: A total of 90 patients were enrolled and treated with rituximab infusions at 375 mg/m2 once weekly for 4 weeks. Central pathology review revealed that histologically, 81 patients had indolent B-cell lymphoma or MCL: 59 with follicular lymphoma, 17 with MCL, four with marginal zone lymphoma and one with lymphoplasmacytoid lymphoma. Of these, four were ineligible due to violation of other eligibility criteria. Pre-treatment variables affecting toxicities were analyzed for all 90 patients, and those affecting response and progression-free survival (PFS) were analyzed for 77 eligible patients with confirmed indolent B-cell lymphoma or MCL. The relationship between serum rituximab levels and efficacy was also analyzed for 66 eligible patients. RESULTS: Hematological toxicities (grade > or =3) occurred more frequently in females (P <0.05), and thrombocytopenia and leukopenia were more frequent in patients with high lactate dehydrogenase (LDH) levels (P <0.05). Non-hematological toxicities (grade > or =2) were more frequent in patients with extranodal disease or bone marrow involvement. The overall response rate (ORR) in patients receiving one prior chemotherapy regimen was higher than those receiving two or more regimens (P <0.05). The median PFS was shorter in MCL patients, in those with extranodal disease, or in those receiving two or more prior chemotherapy regimens (P <0.01). The PFS intervals of patients with higher serum rituximab levels (> or =70 microg/ml) immediately before the third infusion were longer than in other patients (P <0.01). CONCLUSIONS: Several prognostic factors and serum rituximab levels are useful for predicting the toxicity and efficacy of rituximab monotherapy.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/mortality , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/mortality , Adult , Aged , Analysis of Variance , Antibodies, Monoclonal, Murine-Derived , Biopsy, Needle , Confidence Intervals , Disease-Free Survival , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug-Related Side Effects and Adverse Reactions , Female , Humans , Japan , Lymphoma, B-Cell/pathology , Lymphoma, Mantle-Cell/pathology , Male , Maximum Tolerated Dose , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Probability , Risk Factors , Rituximab , Survival Rate , Treatment Outcome
16.
Nucleic Acids Res ; 29(20): 4206-14, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11600709

ABSTRACT

We examined the replication fidelity of an Arg660Ser (R660S) mutant of Thermus aquaticus DNA polymerase I (Taq pol I). In a forward mutation assay, R660S showed a marked reduction in T-->C transitions, one of the most frequent errors made by the wild-type enzyme. Steady-state kinetics showed that R660S discriminates against dGTP incorporation at a template T 13-fold better than the wild-type. R660S was also 3.2-fold less efficient than the wild-type at extending a T:dG mismatch. These results indicate that R660S has enhanced fidelity during incorporation and extension, which reduces its T-->C transition frequency. Interestingly, R660S also discriminated correct from incorrect nucleotides at the incorporation step of C:dATP, A:dATP, G:dATP and C:8-OH-dGTP mispairs 28-, 6.0-, 4.1- and 6.8-fold better, respectively, than the wild-type, although it may not always be as accurate as the wild-type at the extension step. A structural model suggests that Arg660 may participate in two interactions that influence fidelity; the guanidinium group of Arg660 might interact with the incoming guanine base at the major groove and it might compete for forming another interaction with the primer terminus. Substituting Arg with Ser may eliminate or alter these interactions and destabilize the closed complex with incorrect substrates. Our data also suggest that T:dGTP and C:dATP base pairs form 'wobble' structures at the incorporation step of Taq pol I.


Subject(s)
Base Pair Mismatch , DNA Replication , Point Mutation , Taq Polymerase/genetics , Taq Polymerase/physiology , Arginine/genetics , Deoxyguanine Nucleotides/metabolism , Evolution, Molecular , Kinetics , Models, Molecular , Nucleic Acid Conformation , Nucleotides/metabolism , Taq Polymerase/metabolism
17.
Biochemistry ; 40(38): 11571-7, 2001 Sep 25.
Article in English | MEDLINE | ID: mdl-11560507

ABSTRACT

Using 28 chemically well-defined compounds containing D-erythro-sphingosine and its analogues, we analyzed structure-activity relationships for DNA primase inhibition. Biochemical studies demonstrated a positively charged amino group at C2 and a long aliphatic chain to be absolutely required for inhibition. Whereas C2-amino group is intact, sphingosine 1-phosphate was totally inactive. This result could be due to cancellation of positive charge of the amino group by the interaction with negatively charged C1-phosphate, since simulations with the software INSIGHT II showed these two groups to be close enough to interact. The hydroxyl group at C3 and trans-double bond at C4-C5 were also found to be important for the inhibition. Dehydroxylation of C3, as well as saturation or cis-conversion of the trans-double bond led to decrease of inhibitory activity. Despite saturation of the double bond, introduction of a hydroxyl group into C4 of dihydrosphingosine resulted in restoration of inhibition. Conversion of the double bond into a triple bond did not abolish but rather enhanced the inhibitory activity. Among sphingosine stereoisomers, the naturally occurring D-erythro-sphingosine proved to be the strongest inhibitor. To ascertain the contribution of the total conformation to the inhibition, especially of the long aliphatic chain, we constructed a 3D-quantitative structure-activity relationship model using the computer program Catalyst/HipHop on the basis of information described above. Analysis of the hypothesis model for active compounds revealed that the orientation of aliphatic chain, represented by the dihedral angle of C2-3-4-5, correlated well with the inhibition. Modifications such as deletion of the hydroxyl group at C3 or saturation of the C4-C5 double bond caused shifts in the dihedral angle of C2-3-4-5, with concomitant decrease in inhibitory activity.


Subject(s)
DNA Primase/antagonists & inhibitors , DNA Primase/chemistry , Sphingosine/analogs & derivatives , Sphingosine/pharmacology , Animals , Cattle , DNA Polymerase I/metabolism , Molecular Structure , Quantitative Structure-Activity Relationship , Sphingosine/chemistry , Stereoisomerism , Structure-Activity Relationship , Thymus Gland/enzymology
19.
J Histochem Cytochem ; 49(7): 845-55, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11410609

ABSTRACT

Cell type-specific localization of sphingosine kinase 1a (SPHK1a) in tissues was analyzed with a rabbit polyclonal antibody against the 16 C-terminal amino acids derived from the recently reported mouse cDNA sequence of SPHK1a. This antibody (anti-SPHK1a antibody) can react specifically with SPHK1a of mouse, rat, and human tissues. Utilizing its crossreactivity to human SPHK1a, the cell-specific localization of SPHK1a in human tissues was histochemically examined. Strong positive staining for SPHK1a was observed in the white matter in the cerebrum and cerebellum, the red nucleus and cerebral peduncle in the midbrain, the uriniferous tubules in the kidney, the endothelial cells in vessels of various organs, and in megakaryocytes and platelets. The lining cells of sinusoids in the liver and splenic cords in the spleen showed moderate staining. Columnar epithelia in the intestine and Leydig's cells in the testis showed weak staining patterns. In addition, TPA-treated HEL cells, a human leukemia cell line, showed a megakaryocytic phenotype accompanied with increases in immunostaining of both SPHK1a and SPHK enzyme activity, suggesting that SPHK1a may be a novel marker of megakaryocytic differentiation and that this antibody is also useful for in vitro study of differentiation models.(J Histochem Cytochem 49:845-855, 2001)


Subject(s)
Phosphotransferases (Alcohol Group Acceptor)/metabolism , Animals , Antibodies , Blotting, Western , CHO Cells , COS Cells , Cell Differentiation , Cricetinae , Cross Reactions , Humans , Immunohistochemistry , Organ Specificity , Phosphotransferases (Alcohol Group Acceptor)/immunology , Precipitin Tests , Rabbits , Transfection , Tumor Cells, Cultured
20.
Intern Med ; 40(12): 1238-40, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11813851

ABSTRACT

Pulmonary infection with cavitation causes severe respiratory symptoms if the cavity has a communication with main bronchus, through which fluid flows out into trachea. In this report a young male with lung cancer invading an adjacent pre-existent fungus cavitary lesion is presented. Cancer invasion led to broncho-cavitary communication and caused massive intrabronchial aspiration. Subsequently, the cancer destroyed the thoracic wall, and a cavitary-cutaneous fistula developed which relieved symptoms as if treated with open drainage.


Subject(s)
Bronchial Fistula/etiology , Carcinoma, Large Cell/complications , Cutaneous Fistula/etiology , Hemorrhage/etiology , Lung Neoplasms/complications , Adult , Carcinoma, Large Cell/pathology , Cryptococcosis/complications , Cryptococcus neoformans/isolation & purification , Fatal Outcome , Humans , Lung Diseases, Fungal/complications , Lung Neoplasms/pathology , Male , Neoplasm Invasiveness , Suction
SELECTION OF CITATIONS
SEARCH DETAIL
...